PreveCeutical Closes Initial Tranche of Non-Brokered Private Placement
Vancouver, British Columbia--(Newsfile Corp. - October 22, 2026) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H0) (the "Company" or "PreveCeutical"), is pleased announce that, further to its news release dated September 28, 2026, it has closed an initial tranche (the "Initial Tranche") of its previously announced $600,000 non-brokered private placement (the "Offering"), which Initial Tranche consisted of the issuance of 5,200,000 units
Biotechnology, Pharmaceuticals, Health
2026-10-22 5:24 PM EDT | PreveCeutical Medical Inc.
TelyRx to Host Third Quarter 2026 Financial Results Conference Call on Friday, November 6, 2026 at 8:30 am ET
Clearwater, Florida--(Newsfile Corp. - October 22, 2026) - TelyRx Holdings Inc. (TSX: TELY) (OTCQX: TELYF) ("TelyRx" or the "Company"), a vertically integrated, technology-enabled healthcare and pharmacy services company, today announced it will host a conference call and webcast to discuss its third quarter 2026 financial results on Friday, November 6, 2026, at 8:30 a.m. Eastern Time (ET). The Company expects to report its third quarter 2026 financial results for the period end
Healthcare and Hospitals, Health
2026-10-22 7:00 AM EDT | TelyRx
Rise Nano Optics Announces Proposed Non-Brokered Private Placement of Up to C$5 Million
Financing intended to accelerate SpectraGuard™ commercialization, expand optical industry partnerships and support manufacturing growth NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Recent Highlights: FDA Registration: Rise successfully completed FDA Class 1 Medical Device Classification and Re
2026-10-22 7:00 AM EDT | Rise Nano Optics Ltd.
The Untold Story of Rick Hansen's Man In Motion World Tour Comes to the Big Screen Across Canada in November
Richmond, British Columbia--(Newsfile Corp. - October 21, 2026) - Man In Motion: The Rick Hansen Story will be a special event release by Cineplex in selected theatres across Canada on November 1 and 3. Tickets are now on sale. The theatrical release follows the film's world premiere at the Toronto International Film Festival (TIFF), where it received an honourable mention for the Best Canadian Feature Film Award, and its hometown premiere at the Vancouver International Film Festival
Entertainment, Healthcare and Hospitals, Publishing / Informational Services, Health
2026-10-21 10:20 AM EDT | Rick Hansen Foundation
Rapid Dose Therapeutics Ships QuickStrip(TM) Production Line to Callan JMB's Texas cGMP Facility
Burlington, Ontario--(Newsfile Corp. - October 21, 2026) - Rapid Dose Therapeutics Corp. (CSE: DOSE) (OTCQB: RDTCF) ("RDT" or the "Company"), a Canadian biotechnology company specializing in oral thin-film drug delivery technology, today announced that it has shipped a complete QuickStrip™ production line to Callan JMB Inc. (NASDAQ: CJMB) ("Callan JMB") for planned installation at its cGMP facility in Texas, United States. The shipment advances the collaboration outlined in C
2026-10-21 9:16 AM EDT | Rapid Dose Therapeutics Corp.
HPN Holdings, Inc. (KICK) Announces Orange Insurance Services' Continued Agent Growth and Planned Texas Expansion for Q1 2027
Oak Brook, Illinois--(Newsfile Corp. - October 21, 2026) - Orange Underwriters, LLC DBA Orange Insurance Services ("Orange"), a technology-driven provider of non-standard automobile insurance, today announced that its growth in appointed insurance agencies continues to significantly exceed the company's original targets. Building on that momentum, Orange also announced plans to expand into Texas during the first quarter of 2027. Since launching operations in Florida, Orange has e
2026-10-21 9:00 AM EDT | HPN Holdings, Inc.
Custom Health to Close the Market at the TSX on October 22, 2026, and Announces Appointments of Chief Commercial and Strategy Officer and Chief Compliance and Regulatory Officer
Custom Health will close the market at the Toronto Stock Exchange on October 22, 2026, to celebrate the Company's recent listing on the TSX Exchange. Mike Palackdharry has been appointed Chief Commercial and Strategy Officer, bringing more than 30 years of experience in commercial strategy, enterprise sales, business development, and strategic partnerships. Christina Garcia has been appointed Chief Compliance and Regulatory Officer, bringing more than 15
Technology, Pharmaceuticals, Health
2026-10-21 6:00 AM EDT | Custom Health Holdings Inc.
LIS Technologies Bolsters its Executive Team with the Addition of 40-Year Nuclear Industry Veteran Scott Hyman as its Director of Nuclear Fuels Marketing
Oak Ridge, Tennessee--(Newsfile Corp. - October 20, 2026) - LIS Technologies Inc. ("LIST" or "the Company"), a developer of proprietary advanced laser technology and the only U.S.-origin and patented laser uranium enrichment company, today announced that Scott Hyman has joined LIST as its Director, Nuclear Fuels Marketing. Mr. Hyman's addition brings nearly 40 years of nuclear industry experience to LIST's leadership team. In his new role at LIST, he is responsible for identifyin
Technology, Mining and Metals, Energy, Health
2026-10-20 8:59 AM EDT | LIS Technologies Inc.
Adia Med Sells 7% Economic Interest in Adia Labs to CEO Larry Powalisz for $350,000 in Cash
Winter Park, Florida--(Newsfile Corp. - October 20, 2026) - Adia Med, Inc. (OTCQB: ADIA) today announced that its Chief Executive Officer, Larry Powalisz, purchased a 7% economic interest in Adia Labs LLC for $350,000 in cash. Under the completed Membership Interest Purchase Agreement, Powalisz purchased seven membership units at $50,000 per unit. The Company has filed a Current Report on Form 8-K relating to the transaction.
Healthcare and Hospitals, Health
2026-10-20 8:00 AM EDT | Adia Med Inc.
Altrova Health to Host Investor Q&A Session on Tuesday, October 20 at 10:00 A.M. ET
Toronto, Ontario--(Newsfile Corp. - October 20, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") today reminds shareholders and investors that it will host a live question-and-answer (Q&A) session on Tuesday, October 20, 2026 at 10:00 a.m. ET. Further to the Company's news release dated October 19, 2026, announcing the first U.S. sale of 2,000 units of its O-Spray™ product, management will discuss the an
2026-10-20 7:07 AM EDT | Altrova Health Inc.
TempraMed Announces LIFE Offering up to C$8 Million to Accelerate Global Expansion and Fulfilment of Forecasted Demand
Recent Highlights: Record sales: July 2026 sales were about US$522K1, the best month in the company's history, and August was about US$403K, its second-best. Run rate revenue of ~US$5.5M Sales for the first eight months of 2026 were about US$2.07M, already above the US$1.8M booked for all of 2025. Growing patent portfolio: 4 new global patents granted in 2026, for a total of Global distribut
Technology, Biotechnology, Pharmaceuticals, Health
2026-10-20 7:00 AM EDT | TempraMed Technologies Ltd.
FendX Announces Appointment of Daryl Rebeck to Board of Directors
Vancouver, British Columbia--(Newsfile Corp. - October 20, 2026) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D0) (the "Company" or "FendX"), a technology company developing surface-protection solutions to reduce the spread of harmful pathogens, is pleased to announce the appointment of Mr. Daryl Rebeck to the board of directors, effective October 19, 2026. Mr. Rebeck's appointment follows the resignation of Mr. Pierre Soulard. Mr. Rebeck is a Cana
Technology, Healthcare and Hospitals, Health
2026-10-20 7:00 AM EDT | FendX Technologies Inc.
Custom Health Highlights Early Results with BKC Pain Specialists, Supporting Expansion of Chronic Pain Program
Custom Health's existing commercial program with BKC Pain Specialists & Regenerative Medicine Clinic in Ohio is demonstrating early results through the integration of in-home medication technology, pharmacy services and pharmacist-led clinical support for patients managing complex chronic pain. The program provides continuous visibility into patients' medication use and experiences between physician visits, enabling personalized patient engagement, pharmacist-
Technology, Pharmaceuticals, Health
2026-10-20 6:00 AM EDT | Custom Health Holdings Inc.
WELL Health Strengthens Privacy and AI Governance Leadership with Appointment of Samara Starkman as Chief Privacy Officer and Vice President, Legal & Regulatory
WELL appoints recognized privacy and healthcare law expert Samara Starkman as Chief Privacy Officer and Vice President, Legal & Regulatory, to lead enterprise privacy, AI governance and healthcare regulatory strategy across the organization. Ms. Starkman previously led the privacy department at Cancer Care Ontario (now part of Ontario Health), co-founded INQ Consulting and was a Partner at INQ Law, advising major Ontario hospitals, pharmaceutica
Technology, Computer Software, Healthcare and Hospitals, Health
2026-10-20 6:00 AM EDT | WELL Health Technologies Corp.
CardioComm Solutions and CancerCare Manitoba Launch Remote QT/QTc Interval Monitoring Pilot for Breast Cancer Patients
Toronto, Ontario--(Newsfile Corp. - October 19, 2026) - CardioComm Solutions, Inc. (TSXV: EKG) ("CardioComm" or the "Company") announces a collaboration with CancerCare Manitoba ("CCMB") on a pilot study evaluating remote electrocardiogram ("ECG") monitoring for potential QT/QTc interval prolongation after patients begin selected breast cancer drug therapies. During the approximately one-year pilot, patients will use CardioComm's HeartCheck™ CardiBeat handheld ECG monitor f
Technology, Healthcare and Hospitals, Health
2026-10-19 5:00 PM EDT | CardioComm Solutions, Inc.
Altrova Health Announces First U.S. Sale of 2,000 O-Spray Units
Toronto, Ontario--(Newsfile Corp. - October 19, 2026) - Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) ("Altrova Health" or the "Company") today announced the sale of 2,000 units of its O-Spray™ product pursuant to a sales agreement dated October 17, 2026, to a distributor of peptide products with a large network of healthcare practitioners and retail channels (the "Purchaser"). The sale marks the Company's entry into the United States market. O-Spr
2026-10-19 2:21 PM EDT | Altrova Health Inc.
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
King of Prussia, Pennsylvania--(Newsfile Corp. - October 19, 2026) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio Pharmaceuticals announced today that Robert Bitterman, CEO and Chairman of the Board, will present an overview of the Company's INTASYL® siRNA therapeutic platform, including its lead clinical ca
Biotechnology, Healthcare and Hospitals, Pharmaceuticals, Health
2026-10-19 9:53 AM EDT | Phio Pharmaceuticals Corp.
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - October 19, 2026) - BetterLife Pharma Inc. (CSE: BETR) (OTCQB: BETRF) (FSE: NPAU) ("BetterLife" or the "Company"), a biotechnology company developing BETR-001 for chronic cluster headache and chronic migraine, today announced the appointment of Professor Richard B. Lipton, MD, as Co-Chair of its Scientific Advisory Board ("SAB"). Professor Lipton joins Professor Peter Goadsby, MD, PhD, FRS, whose appointment as Co-Chair was announced on
2026-10-19 8:00 AM EDT | BetterLife Pharma Inc.
CBIH Announces Expanded Research Strategy at the Intersection of Endocannabinoid Science and Biological Medicine
Houston, Texas--(Newsfile Corp. - October 19, 2026) - Cannabis Bioscience International Holdings, Inc. (OTC Pink: CBIH), a public company trading on the OTC Markets under the ticker symbol CBIH, announced an expansion of its scientific research strategy focused on the intersection of endocannabinoid biology, precision medicine, and the development of intellectual property with potential biomedical applications. "We are witnessing a new era in the history of medicine: an era in which hum
Biotechnology, Pharmaceuticals, Cannabis, Health
2026-10-19 7:00 AM EDT | Cannabis Bioscience International Holdings
Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform
Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum&#
Biotechnology, Pharmaceuticals, Health
2026-10-19 3:15 AM EDT | Defence Therapeutics Inc.